Circulation, Vol 76, 1312-1318, Copyright © 1987 by American Heart Association
MB Murphy, CE McCoy, RR Weber, ED Frederickson, FL Douglas and LI Goldberg
Activation of dopamine1 (DA1) receptors relaxes vascular smooth muscle,
especially in the renal vascular bed. Fenoldopam, the first selective
DA1-receptor agonist that can be administered to man, was infused
intravenously in 17 patients with essential hypertension (mean blood
pressure 152/101 mm Hg). It reduced blood pressure in a dose-dependent
fashion at doses between 0.025 and 0.5 microgram/kg/min and the
antihypertensive effect was sustained during 2 hr infusions. In 10 patients
studied during free-water diuresis, fenoldopam increased renal plasma flow
by 42%, glomerular filtration rate by 6%, and sodium excretion by 202%,
while lowering mean arterial pressure by 12% (all p less than .05). Similar
promotion of sodium excretion was observed during blood pressure reduction
in six additional patients studied without water loading. Pronounced
enhancement of renal function in spite of blood pressure reduction suggests
that fenoldopam might have a special role in the treatment of patients with
hypertension and renal impairment.
ARTICLES
Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam
Department of Pharmacological and Physiological Sciences, University of Chicago, IL 60637.
This article has been cited by other articles:
 |
|
 |
|
  T. Bove, G. Landoni, M. Grazia Calabro, G. Aletti, G. Marino, E. Cerchierini, G. Crescenzi, and A. Zangrillo Renoprotective Action of Fenoldopam in High-Risk Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Clinical Trial Circulation, June 21, 2005; 111(24): 3230 - 3235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Weisbord and P. M. Palevsky Radiocontrast-Induced Acute Renal Failure J Intensive Care Med, March 1, 2005; 20(2): 63 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 J. N. Ghansah and J. T. Murphy Complications of Major Aortic and Lower Extremity Vascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 335 - 361. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Morelli, M. Rocco, G. Conti, A. Orecchioni, R. Alberto De Blasi, F. Coluzzi, and P. Pietropaoli Monitoring Renal Oxygen Supply in Critically-Ill Patients Using Urinary Oxygen Tension Anesth. Analg., December 1, 2003; 97(6): 1764 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone, P. A. McCullough, J. A. Tumlin, N. E. Lepor, H. Madyoon, P. Murray, A. Wang, A. A. Chu, G. L. Schaer, M. Stevens, et al. Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy: A Randomized Controlled Trial JAMA, November 5, 2003; 290(17): 2284 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Lewis Pharmacological Review of Postoperative Hypertension Journal of Pharmacy Practice, April 1, 2002; 15(2): 135 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 M. B. Murphy, C. Murray, and G. D. Shorten Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sehgal, P. H. Arger, A. C. Silver, J. A. Patton, H. M. Saunders, A. Bhattacharyya, and C. P. Bell Renal Blood Flow Changes Induced with Endothelin-1 and Fenoldopam Mesylate at Quantitative Doppler US: Initial Results in a Canine Study Radiology, May 1, 2001; 219(2): 419 - 426. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. G. Ramsay Cardiac Management in the ICU Chest, May 1, 1999; 115(suppl_2): 138S - 144S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hussain and M. F. Lokhandwala Renal Dopamine Receptor Function in Hypertension Hypertension, August 1, 1998; 32(2): 187 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Gretler, W. J. Elliott, M. Moscucci, R. W. Childers, and M. B. Murphy Electrocardiographic Changes During Acute Treatment of Hypertensive Emergencies With Sodium Nitroprusside or Fenoldopam Arch Intern Med, December 1, 1992; 152(12): 2445 - 2448. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Saito, H. Kawabe, C. Hasegawa, Y. Iwaida, H. Yamakawa, T. Saruta, E. Takeshita, S. Nagano, and T. Sekihara Effect of L-dopa in Young Patients with Hypertension Angiology, September 1, 1991; 42(9): 691 - 695. [Abstract] [PDF]
|
|
|
|
|
|
W. B. White and S. E. Halley Comparative Renal Effects of Intravenous Administration of Fenoldopam Mesylate and Sodium Nitroprusside in Patients With Severe Hypertension Arch Intern Med, April 1, 1989; 149(4): 870 - 874. [Abstract] [PDF]
|
|